















low	 toxicity	 that	 could	 improve	 mRNA	 transfection	 efficiency.	 We	 have	 recently	 introduced	 the	 potential	 of	
polyhydrazones	and	 the	 importance	of	 the	polymerization	degree	 for	 the	delivery	of	 siRNA	and	plasmid	DNA.	Here,	we	
demonstrate	 that	 this	 technology	can	be	easily	adapted	 to	 the	more	 interesting	complexation	and	delivery	 inside	 living	
cells	 cells	 of	 messenger	 RNA.	 The	 polyplexes	 resulting	 from	 the	 combination	 of	 the	 amphiphilic	 polyhydrazone	 were	






The	 delivery	 of	 nucleic	 acids	 (DNA	 or	 RNA)	 as	
therapeutic	 agents	 has	 focused	 the	 interest	 of	 chemists,	
pharmacists	 and	 materials	 scientists.1	 Therapeutic	 nucleic	
acids	 have	 been	 used	 to	 regulate	 gene	 expression	 as	 a	
treatment	for	heritable	and	acquired	diseases,	including	the	
use	 of	 DNA-based	 vaccines,	 antiviral	 therapies	 or	 cancer	
immunotherapy.2–4	 Several	 reports	 highlight	 the	 great	
potential	 of	 messenger	 RNA	 (mRNA)	 in	 chemical	 biology	
and	 for	 the	 treatment	 of	 different	 diseases.5–11	mRNA	has	
an	ideal	transitory	activity	and	it	does	not	need	to	cross	the	
nuclear	envelope.12	These	intriguing	properties	have	fuelled	
the	 search	 of	 messenger	 RNA	 therapies	 and	 for	 instance,	
mRNA	 has	 been	 successfully	 used	 in	 clinical	 trials	 such	 as	
cancer	 immunotherapy,13	 the	 treatment	 of	 infectious	
diseases14	 and	 in	 regenerative	 medicine.15	 Different	 from	
small	interfering	RNA	(siRNA),	the	therapeutic	use	of	mRNA	
is	 based	 on	 the	 potential	 to	 introduce	 new	 genetic	
information	 for	 the	 expression	 of	 therapeutic	 or	 essential	
proteins.	 However,	 mRNA	 has	 important	 advantages	 over	
the	delivery	of	plasmid	DNA	(pDNA).	mRNA	target	is	located	
in	 the	 cytosol	 of	 the	 cell,	 whereas	 pDNA	 functionality	
requires	 reaching	 the	 nuclei	 and	 can	 be	 dependent	 on	
nuclear	 membrane	 breakdown	 during	 cell	 division.12	
Moreover,	the	risk	of	insertional	mutagenesis,	associated	to	
pDNA,	can	be	excluded	when	using	mRNA.16,5	However,	the	
clinical	 translation	 of	mRNA	 therapy	 is	 severely	 limited	 by	
the	lack	of	stable	and	effective	delivery	vehicles.		
The	 use	 of	 viruses	 as	 vectors	 for	 gene	 delivery	 comprises	
the	majority	of	the	current	literature	on	this	topic,	as	could	
be	 expected	 from	 their	 higher	 in	 vivo	 transfection	
efficiency.17	 However,	 the	 biological	 application	 of	 viral	
vectors	 has	 important	 limitations	 such	 as	 low	 DNA	
packaging	 capacity,	 insertional	 mutagenesis,	 undesirable	
immune	 responses	 and	 the	 critical	 problem	 of	 synthetic	
scaling	 up	 and	 production	 in	 large	 quantities.17	 Non-viral	
vectors,	 such	 as	 peptides,18–21	 lipid	 nanoparticles22–24	 and	
polymers,25–28	have	been	intensively	investigated	for	nucleic	
acid	delivery	as	a	safer,	more	reproducible	and	inexpensive	
alternative.	 The	 importance	 of	 non-viral	 vectors	 is	
highlighted	 by	 the	 recent	 approval	 of	 patisiran,	 a	 lipidic	
formulation	 of	 siRNA,	 for	 the	 treatment	 of	 Hereditary	
Transthyretin	Amyloidosis.29		
Supramolecular	 chemistry30	 has	 also	 been	 explored	 and	
applied	in	the	search	of	conceptually	new	non-viral	vectors	
based	 in	 lipids,31	 cyclodextrins,32	 pillararenes,33	
proteins,34,35	 peptides,36,37	 nanotubes38	 and	 other	
architectures.39,40	 Dynamic	 covalent	 chemistry	 has	 also	
recently	 emerged	 as	 a	 promising	 tool	 for	 delivery	










non-viral	 vectors,	 polymers	 stand	 out	 as	 excellent	
transfection	 agents	 due	 to	 their	 excellent	 properties	 and	
simple	 synthesis	 in	 a	 range	 of	 sizes.3,43–45	 In	 addition,	
polymers	provide	a	multivalent	scaffold	for	supramolecular	
electrostatic/hydrophobic	interactions	with	the	nucleic	acid	
cargo,	 which	 is	 key	 for	 nucleic	 acid	 complexation,	 cellular	
recognition46	 and	 response	 to	 external	 stimuli.47	 As	 a	
consequence,	 polymers	 are	 one	 of	 the	 most	 promising	
synthetic	 materials	 for	 gene	 therapy	 due	 to	 their	
versatility.3,17,48	 Although	 very	 interesting	 recent	 designs	




We	 have	 recently	 reported	 the	 in	 situ	 conjugation	 of	
polyhydrazide	 scaffolds	 with	 cationic	 and	 hydrophobic	
aldehydes	 to	 obtain	 polyhydrazone	 vectors	 as	 an	 ideal	
strategy	for	the	identification	of	new	polymeric	vectors	for	
small	 interfering	 RNA	 (siRNA)	 and	 plasmid	 DNA	 in	 human	
HeLa	 cells.25,26	 These	 polyhydrazides	 can	 be	 functionalized	
with	 different	 aldehydes	 moieties	 in	 situ,51	 that	 is,	 in	
aqueous	 environment	 and	 without	 any	 isolation	 or	
purification	 steps.25,26	 The	 resulting	 amphiphilic	
polyhydrazones	 can	 be	 then	 combine	with	 the	DNA	 cargo	
and	 screened	 for	 the	 delivery	 of	 nucleic	 acids	 (i.e.	 siRNA,	
pDNA).	 However,	 the	 potential	 application	 of	 these	
promising	 polyhydrazones	 for	 the	 delivery	 of	 the	 more	
challenging	 mRNA	 still	 remained	 elusive.	 Prompted	 by	 its	
strong	 therapeutic	 possibilities	 and	 by	 the	 industrial	
interest	in	new	materials	for	mRNA	delivery,	we	decided	to	
study	 the	 potential	 of	 our	 methodology	 for	 the	 more	
challenging	delivery	of	the	highly	sensitive	messenger	RNA.	
Here,	 we	 report	 the	 application	 of	 the	 in	 situ	
functionalization	 of	 polyhydrazones	 for	 the	 delivery	 of	
mRNA	to	Hek293	cells.	Polyhydrazides	were	modified	with	a	
cationic	 and	 six	 different	 hydrophobic	 aldehydes	 to	 yield	
amphiphillic	 polyhydrazones,	 which	 were	 tested	 for	
intracellular	delivery	of	mRNA	encoding	for	the	synthesis	of	
the	 enhanced	 green	 fluorescent	 protein	 (EGFP).	 In	
particular,	 this	 work	 confirms	 that	 a	 higher	 molecular	
weight	 of	 poly(acryloyl	 hydrazide)	 and	 a	 new	hydrophobic	
aldehydes,	 none	 of	 which	 were	 previously	 reported,	 are	
required	to	achieve	efficient	mRNA	transfection.	The	results	
reported	here	confirmed	the	potential	of	these	polymers	to	
efficiently	 complex	 and	 deliver	mRNA	with	 high	 efficiency	
and	 low	 cytotoxicity	 even	 at	 low	 polyhydrazone	
concentrations.	
2.	Results	and	Discussion	
2.1	 Design	 and	 polyhydrazone	 formation.	 Following	 initial	
transfection	experiments	that	showed	that	shorter	poly(acryloyl	
hydrazide)s	 were	 unable	 to	 deliver	 longer	 nucleic	 acids,	 the	
synthesis	 of	 poly(acryloyl	 hydrazide)	 Pn	was	 adapted	 from	 our	
previous	work.25,26,51	In	this	case,	free-radical	polymerization	
using	 2-aminoethanethiol	 as	 a	 chain-transfer	 agent	 was	
employed	 to	 afford	 a	 poly(acryloyl	 hydrazide)	 of	
significantly	higher	molecular	weight	that	those	reported	by	
us	so	far	(See	ESI†	for	full	details).21,22	Following	previously	
reported	 experimental	 conditions,	 polyhydrazide	 P	 was	






Figure	 2.	 Polyhydrazone	 reaction	 and	 initial	 screening.	 (A)	 Schematic	 representation	 of	 the	 reaction	 of	 the	 polyhydrazide	 P	 with	 the	




above	 each	 panel.	 Scale	 bars	 represent	 200	 nm.	 (C)	 Percentage	 of	 transfection	 of	 EGFP-mRNA	 in	 Hek293	 cells	 using	 three	 different	
hydrophobic	aldehydes.	Error	bars	indicate	the	standard	deviation	of	three	replicates.	
aldehydes	 (Tm)	 in	 100	 mM	 acetate	 buffer:DMSO	 (3:1)	 at	
60oC	during	2	h.51	Due	to	the	high	Mw	of	the	poly(acryloyl	
hydrazide)	 used,	 a	 slightly	 higher	 proportion	 of	 aqueous	
buffer	 had	 to	 be	 employed	 (i.e.	 3:1	 for	mRNA	 delivery	 as	
compared	 to	 1:1	 for	 pDNA	 delivery26).	 After	 securing	
complete	 solubility	 of	 all	 the	 reagents,	 the	 resulting	
amphiphilic	polyhydrazones	were	directly	combined	mRNA	
without	 further	 purification	 (Fig.	 2A).	 As	 previously	
reported,25,26,30	 we	 decided	 to	 employ	 different	
hydrophobic	 aldehydes	 but	 to	 keep	 fixed	 the	 cationic	
guanidinium	aldehyde	 (T1),	because	 its	high	pKa	 (pKa~12.5)	
ensures	 protonation	 at	 physiological	 pH,	 which	 enhances	
mRNA	 complexation	 by	 electrostatic	 interactions.	 The	




hydrophobic	 aldehydes	 and	X	 is	 the	molar	 fraction	 of	 the	
guanidinium	aldehyde	in	the	mixture	(Fig.	2A).	
2.2	 mRNA	 delivery	 by	 polyhydrazones.	 A	 preliminary	
mRNA	transfection	assay	was	performed	in	Hek293	cells	 in	
order	 to	 select	 combinations	 of	 aldehydes	 for	 further	
optimisation	 (Fig	 2B	 and	2C).	Accordingly,	 polyhydrazide	P	
was	 incubated	 with	 guanidinium	 aldehyde	 (T1)	 and	 three	
different	 hydrophobic	 aldehydes	 (myristoleic	 (T2),	
palmitoleic	 (T3)	 and	 petroselinic	 (T4)	 aldehydes)	 using	 the	
same	ratio	of	hydrophilic	to	hydrophobic	aldehyde	that	we	
had	 previously	 reported	 as	 optimal	 for	 the	 delivery	 of	
plasmid	 DNA	 (XT1=0.7,	 XTm=0.3).
26	 While	 an	 excess	 of	
aldehyde	 was	 used	 during	 the	 post-polymerization	
modification	 of	 poly(acryloyl	 hydrazide)	 (7	 equiv.	 per	
monomer),	no	transfection	 is	observed	with	the	aldehydes	
alone.18,19,25,52	 The	 hydrazone-activated	 polymers	 were	
then	incubated	with	the	EGFP-mRNA	in	DMEM	medium	for	
30	min	at	room	temperature	(See	experimental	section	for	
full	 details)	 and	 the	 resulting	 polyplexes	 incubated	 with	
Hek293	cells	 for	5	hours	 in	DMEM.	The	medium	was	 then	
replaced	by	DMEM	containing	10%	FBS	and	1%	of	Penicillin-
Streptomycin-Glutamine	 Mix,	 and	 fluorescence	 was	
quantified	 by	 flow	 cytometry	 24	 hours	 post-transfection	
(Fig.	2C).	While	almost	no	transfection	was	observed	for	the	
palmitoleic	 derivative	 (T3),	 both	 myristoleic	 (T2)	 and	
petroselinic	 (T4)	 aldehydes	 showed	 encouraging	 values	 of	
transfection	by	epifluorescence	microscopy	(Fig.	2B).	These	
results	 were	 in	 agreement	 with	 the	 cytometry	
quantification	that	 indicated	a	30%	of	transfected	cells	per	
well	 for	 the	 certain	 concentrations	 of	 the	 polyhydrazones	
with	the	myristoleic	(T2)	and	the	petroselinic	(T4)	aldehydes	
(Fig.	2C).		
2.3	 Transfection	 optimization	 and	 cell	 viability.	 Having	
confirmed	 the	 delivery	 of	 mRNA	 inside	 Hek293	 cells	 for	
certain	 aldehyde	 combinations,	 we	 then	 performed	 an	
optimization	 of	 the	 aldehyde	 molar	 fraction	 for	 the	 most	





aldehyde	 (Fig.	 3A).	 These	 experiments	 showed	 slightly	
higher	activities	when	the	molar	fraction	of	the	myristoleic	
aldehyde	 was	 increased	 up	 to	 XT1/XT2	 =	 0.5:0.5.	 Finally,	
with	 this	 optimized	 molar	 ratio	 (PT1
0.5/Tm
0.5),	 a	 dose-
response	 transfection	 experiment	 was	 performed	 using	
now	 six	 hydrophobic	 aldehydes.	 Quantification	 of	
transfection	 using	 flow	 cytometry	 showed	 that	 all	 the	
polyhydrazones	 investigated,	 with	 the	 exception	 of	 the	
polyhydrazone	 bearing	 the	 dodecanal	 hydrophobic	
aldehyde,	 were	 capable	 of	 transfecting	 mRNA	 inside	
Hek293	cells	with	good	efficiencies	(Fig	3B).	Once	again,	the	
myristoleic	 aldehyde	 displayed	 the	 highest	 transfection	
value	 (42%	 of	 transfected	 cells	 per	 well),	 suggesting	 that	
myristoleic	 aldehyde	 outcompetes	 the	 rest	 of	 the	
hydrophobic	 aldehydes	 in	 terms	 of	 transfection	 activity.	
Fluorescence	 microscopy	 images	 of	 transfected	 cells	
visually	 confirmed	 the	 high	 efficiency	 of	 myristoleic-
modified	polyhydrazones	as	gene	vectors	(Fig.	3C).	In	order	
to	 compare	 the	 efficiency	 of	 the	 activated	 polyhydrazone	
PT1
0.5/T2
0.5	 with	 single	 component	 formulations	 for	 mRNA	
cell	 delivery,	 we	 decided	 to	 test	 several	 cationic	 and	
amphiphilic	 delivery	 vehicles	 such	 as	 the	 olicationic	
penetrating	peptide	(R8),	the	pore	forming	peptide	(GALA),	
the	 cationic	 lipid	 (DOTAP)	 and	 the	 polyethylenimine	
polymer	 (PEI).	 At	 an	 equal	 low	 weight	 concentration	 (6	
µgr/ml)	 of	 each	 transfecting	 reagent,	 only	 the	 cationic	
polymer	 (PEI)	 achieved	 a	 similar,	 slightly	 lower,	 level	 of	
transfection	 efficiency	 compared	 to	 that	 of	 the	 activated	
polyhydrazone	PT1
0.5/T2
0.5	 (Fig	 3E).	 The	 lack	 of	 transfection	
of	mRNA	 using	 penetrating	 peptides	 vehicles	 and	 cationic	
liposomes,	 at	 low	 vector	 concentration,	 confirmed	 the	
suitability	 of	 activated	 polyhdrazones	 to	 discover	 and	





that	 quantifies	 cell	 viability	 by	 measuring	 mitochondrial	
activity	 upon	 reduction	 of	 the	 MTT	 substrate	 to	 purple	
formazan.	 To	 our	 delight,	 none	 of	 the	 polyhydrazones	
investigated	 showed	 significant	 toxicity	 (Fig	 S1),	 in	
particular	those	derived	from	myristoleic	aldehyde	(Fig.	3D),	




via	 gel	 electrophoresis,	 which	 confirmed	 that	 all	
polyhydrazones	except	those	derived	from	dodecanal	were		
	
Figure	 3.	 Transfection	 optimization	 and	 cell	 viability.	 (A)	 Molar	 ratio	 optimization	 for	 the	 transfection	 of	 EGFP-mRNA	 (1	 ng/µL)	 with	
myristoleic-modified	 polyhydrazones	 (T2)	 at	 different	 concentrations.	 (B)	 Transfection	 efficiency	 of	 the	 polymer	 conjugated	 with	 six	
different	hydrophobic	aldehydes	at	different	concentrations.	EGFP-mRNA	concentration	was	kept	constant	at	1	ng/µL.	Data	is	expressed	
as	 the	mean	 of	 the	 percentage	 of	 transfected	 cells	 in	 three	 replicates.	 (C)	 Bright-field	 images,	 green	 fluorescent	 channel	 and	merged	
images	of	Hek293	 cells	 24	hours	 after	 transfection	with	polyplexes	 formed	with	6	µg/mL	of	 the	myristoleic-modified	polymer	 (XT1:0.5,	











Figure	 4.	 DLS,	 ζ-potential	 and	 gel	 retardation	 assay.	 (A)	 DLS	 intensity	 and	 correlation	 curve	 of	 myristoleic-modified	
polymer/EGFP-mRNA	 polyplexes	 at	 6	 µg/mL	 of	 polyhydrazone,	measured	 in	water.	 (B)	 Zeta	 potential	 (ζ)	 in	millivolts	 (mV)	 of	
myristoleic-modified	 polymer/EGFP-mRNA	 polyplexes	 at	 2,	 4,	 6	 and	 8	 µg/mL	 of	 polyhydrazone,	 measured	 in	 water.	 Data	 is	
expressed	as	mean	of	triplicates;	error	bars	indicate	standard	deviation.	(C)	Gel	retardation	assay	with	the	myristoleic-modified	
polyhydrazone.	EGFP-mRNA	 and	PT1T2/EGFPmRNA	 polyplexes	with	 different	 concentrations	 of	 polyhydrazones:	 2,	 4,	 6	 and	 8	
µg/mL.	For	all	experiments	[EGFPmRNA]	=	1	ng/µL.	
able	to	complex	mRNA	(Fig.	4C	and	S2).	These	results	were	




measurements	 were	 performed	 for	 the	 myristoleic	
aldehyde	 polyhydrazones	 hits	 (PT1
0.5T2
0.5,	 Fig.	 4A	 and	 4B).	
DLS	 analysis	 proved	 the	 formation	 of	 polyplexes	 with	
diameters	of	50	to	100	nm,	with	characteristic	polyplex	PdIs	
(~0.3),53	 and	 showed	 the	 progressive	 increase	 in	 zeta	
potential	 with	 increasing	 polymer	 concentration	 (Fig.	 4B).	
These	 results	 are	 in	 agreement	 with	 the	 gel	 experiments,	
where	 the	 polyhydrazone	 was	 able	 to	 provide	 polyplexes	
with	 a	 positive	 net	 charge	 of	 around	 15	 mV,	 enough	 to	
inhibit	 mRNA	 migration	 in	 the	 gel	 at	 all	 the	 tested	
concentrations	(Fig.	4C).	
3.	Conclusions	
The	 objective	 of	 this	 study	 was	 to	 demonstrate	 the	
versatility	 of	 the	 in	 situ	 polyhydrazone	 formation	 as	 an	
excellent	methodology	for	the	 identification	of	amphiphilic	
polymers	to	complex	and	deliver	inside	cells	the	challenging	
messenger	 RNA.	 In	 this	 work,	 a	 high	 molecular	 weight	
poly(acryloyl	 hydrazide)	 was	 easily	 functionalized	 with	 a	
mixture	 of	 guanidinium	 and	 hydrophobic	 aldehydes.	 The	
resulting	 polyhydrazones	 were	 optimized	 with	 different	
hydrophobic	aldehydes	at	different	molar	ratios	to	achieve		
efficient	non-viral	vehicles	for	mRNA	delivery	inside	human	
cells	 (Hek293)	 with	 low	 toxicity.	 Our	 results	 indicate	 that	
amphiphilic	 polyhydrazones	 derived	 from	 unsaturated	
aldehydes	 displayed	 very	 good	 promising	 transfection	
capacity	 of	 the	 challenging	 mRNA,	 a	 nucleic	 acid	 with	 a	
great	potential	in	genetic	engineering	and	gene	therapy.	
4.	Experimental	Section	
4.1	 Materials.	 Poly(acryolyl	 hydrazide)	 was	 synthesized	
using	 controlled	 free	 radical	 polymerization	 (See	 ESI†	 for	
full	details).	The	aldehydes	tested	were	either	commercially	




Avanti	 Polar	 Lipids.	 Penicillin-Streptomycin-Glutamine	Mix,	
Trypsin-EDTA	solution	and	DMEM	(4500	mg/mL	glucose,	L-
glutamine,	sodium	pyruvate	and	sodium	bicarbonate)	were	
purchased	 from	 Fisher	 Scientific.	 Fetal	 bovine	 serum	 was	
purchased	 from	 Sigma-Aldrich.	 The	 selected	 cargo	 (EGFP-
mRNA)	 was	 a	 single-stranded	 EGFP	 encoding	 messenger	
RNA	 of	 996	 nucleotides,	 it	 is	 capped	 and	 polyadenylated	
and	 modified	 with	 5-methoxyuridine.	 This	 mRNA	 was	
purchased	to	TriLink	Biotechnologies.		
4.2	 Conjugation	 of	 poly(acryoyl	 hydrazide)	 with	 aldehyde	
modulators.	In	a	typical	experiment,	poly(acryoyl	hydrazide)	
in	 acetate	 buffer	 (100	mM,	 pH	 =	 0.3)	 was	 reacted	with	 7	
equiv.	 per	 monomer	 of	 different	 molar	 fractions	 of	





give	 a	 final	 monomer	 concentration	 of	 1	 mg/mL	 with	 a	
molar	ratio	XT1=0.5	and	XT2=0.5.	This	mixture	was	shaken	at	
60oC	 for	2	hours.	 The	polyhydrazones	obtained	were	used	
for	 Hek293	 cells	 transfection	 experiments	 without	 further	
purification.	
	4.3	 EGFP-mRNA	delivery.	Human	embryonic	 kidney	 293	
cells	 (Hek293)	 were	 maintained	 in	 Dulbecco’s	 Modified	
Eagle’s	 Medium	 supplemented	 with	 10%	 FBS	 and	 1%	
Penicillin-Streptomycin-Glutamine	Mix	at	37oC/5%	CO2/95%	
humidity	in	an	INCO	108	incubator	(Memmert).	
One	 day	 before	 transfection,	 cells	 were	 seeded	 in	 96-
well	 plates	 at	 a	 concentration	 of	 150000	 cells/mL	 (100	
µL/well).	Transfection	was	done	by	incubation	of	cells	with	
1	ng/µL	of	EGFP-mRNA	and	different	concentrations	of	the	





described	 above.	 The	 solutions	 of	 polymer/EGFP-mRNA	
were	 prepared	 before	 to	 the	 transfection	 experiments	 by	
mixing	 10	 µL	 of	 the	 EGFP-mRNA	 solution	 (20	 ng/µL	 in	
DMEM)	and	35	µL	of	the	polymer	solution	in	DMEM	for	30	
min	 using	 linear	 shaking.	 Then,	 11	 µL	 of	 every	
polymer/mRNA	 mixture	 was	 added	 to	 Hek293	 cells	
previously	 covered	 with	 39	 µL	 of	 DMEM	 without	 FBS	 or	
antibiotics.	Cells	were	 incubated	 for	5	h	prior	 to	exchange	
the	 medium	 for	 DMEM	 (without	 phenol	 red)	 containing	
10%	bovine	foetal	serum	and	1%	of	Penicillin-Streptomycin-
Glutamine	Mix.	
4.4	 Epifluorescence	 microscopy	 of	 transfected	 cells.	
Hek293	 cells	 were	 transfected	 following	 the	 protocol	
described	 above.	 After	 24	 hours	 of	 incubation	 cells	 were	
imaged	under	the	microscope	(Fig.	2B	and	3C).	
4.5	 Flow	 Cytometry.	 Hek293	 cells	 were	 transfected	
following	 the	 procedure	 described	 above.	 One	 day	 after	
transfection,	cells	were	trypsinized	with	100	µL	of	Trypsin-
EDTA	 for	 10	min	 at	 37oC.	 After	 neutralizing	 trypsin	 by	 the	
addition	of	100	µL	of	2	%	FBS	and	5	mM	EDTA	 in	PBS,	cell	
clumps	 were	 broken	 by	 pipetting	 before	 analysing	 on	 a	
Guava	 EasyCyteTM	 cytometer.	 EGFP	 fluorescence	 was	
measured	by	excitation	at	488	nm	and	detection	at	512/18	
nm.	 For	 the	 analysis,	 cells	 with	 typical	 FSC	 and	 SSC	
parameters	were	 selected	and	cells	were	considered	EGFP	
positive	when	 fluorescence	 signal	was	 higher	 than	 that	 of	
the	untreated	cells	 (Fig.	2C,	3A	and	3B).	Data	analysis	was	
performed	with	 InCyte	 software	 included	 in	GuavaSoft	3.2	
(Millipore).	
4.6	Cell	viability	assay.	Cell	viability	was	determined	using	
a	MTT	 assay,	which	 relies	 on	 the	 ability	 of	 cells	 to	 reduce	
the	 water-soluble	 tetrazolium	 salt	 to	 the	 insoluble	
formazan.	 Hek293	 cells,	 seeded	 at	 a	 concentration	 of	
200000	 cells/mL	 the	 day	 before	 to	 transfection,	 were	
incubated	 with	 the	 polyplexes	 as	 previously	 described	




100,	0.1	M	HCl)	were	added	 to	 the	 cells	 for	dissolving	 the	
formazan	 crystals.	 Absorbance	 was	 measured	 at	 570	 nm	
using	 a	 microplate	 reader	 (Infinite	 F200pro,	 Tecan).	 Data	
points	 were	 collected	 in	 triplicate	 and	 values	 were	
normalized	for	untreated	control	cells	(Fig	3D	and	S1).	
4.7	 Hydrodinamic	 Radius	 and	 ζ-Potential.	 For	 gel	
retardation	assay,	35	µL	of	different	 concentrations	of	 the	
freshly	 prepared	 polyhydrazones	 (2-8	 µg/mL	 in	 H2O)	were	
mixed	with	10	µL	of	EGFP-mRNA	solution	(20	ng/µL	in	H2O)	
and	 incubated	 for	 30	 min	 with	 linear	 shaking.	 Before	
measuring,	 955	 µL	 of	 filtered	 H2O	 were	 added	 to	 each	
solution	and	size	and	ζ-potential	were	resolved	in	a	Malvern	
Zetasizer	 NanoZSP	 using	 standard	 disposable	 cuvettes.	 All	
experiments	 were	 done	 in	 triplicate	 at	 25oC	 (Fig.	 4A	 and	
4B).	
4.8	 Gel	 retardation	 assay.	 For	 gel	 retardation	 assay,	
different	 concentrations	 of	 the	 freshly	 prepared	
polyhydrazones	were	mixed	with	the	EGFP-mRNA	in	DMEM	
at	 room	 temperature	 for	 30	 min.	 The	 polyplexes	 and	 a	
solution	of	the	free	EGFP-mRNA	at	the	same	concentration	
were	 loaded	 in	 a	 1%	 agarose	 gel	 containing	 0.5	 µg/mL	 of	
ethidium	bromide	in	TAE	buffer	(40	mM	Tris,	20	mM	acetic	
acid	and	1	mM	EDTA).	Electrophoresis	was	run	at	100V	for	
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